GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Quality Rank

CLDI (Calidi Biotherapeutics) Quality Rank


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Calidi Biotherapeutics Quality Rank Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Calidi Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.